Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue PLoS ONE Année : 2019

Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis

Résumé

Objectives Our objective was to compare the cardiovascular safety of tocilizumab and other biological disease-modifying antirheumatic drugs (bDMARD) in rheumatoid arthritis using a network meta-analysis (NMA). Methods A systematic literature search through May 2018 identified randomized controlled trials (RCT) or observational studies (cohort only) reporting cardiovascular outcomes of tocilizumab (TCZ) and/or abatacept (ABA) and/or rituximab (RTX) and/or tumor necrosis factor inhibitors (TNFi) in rheumatoid arthritis patients. The composite primary outcome was the rate of major adverse cardiovascular outcomes (MACE, myocardial infarction (MI), peripheral artery disease (PAD) and cardiac heart failure (CHF)). Results 19 studies were included in the NMA, including 11 RCTs and 8 cohort studies. We found less events with RTX (5.41 [1.70;17.26]. We found no difference between TCZ and other treatments. Concerning MI, we found no difference between TCZ and csDMARD (4.23 [0.22;80.64]), no difference between TCZ and TNFi (2.00 [0.18;21.84]). There was no difference between TCZ and csDMARD (1.51[0.02;103.50] and between TCZ and TNFi (1.00 [0.06;15.85]) for stroke event. With cohorts and RCT NMA, we found no difference between TCZ and other treatments for MACE (0.66 [0.42;1.03] with ABA, 1.04 [0.60;1.81] with RTX, 0.78[0.53;1.16] and 0.91 [0.54;1.51] with csDMARD), but the risk of myocardial infarction was lower with TCZ compared to ABA (0.67 [0.47;0.97]). We lacked data to compare TCZ and other bDMARD for stoke and MI. Not enough data was available to perform a NMA for CHF and PAD.
Fichier principal
Vignette du fichier
Castagne_PlosOne_2019.pdf (1.89 Mo) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-04329176 , version 1 (07-12-2023)

Identifiants

Citer

Benjamin Castagné, Marie Viprey, Julie Martin, Anne-Marie Schott, Michel Cucherat, et al.. Cardiovascular safety of tocilizumab: A systematic review and network meta-analysis. PLoS ONE, 2019, 14 (8), pp.e0220178. ⟨10.1371/journal.pone.0220178⟩. ⟨hal-04329176⟩
43 Consultations
18 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More